Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-11-02 00:00:00 ET · period of report 2023-10-31 · accession 0000950170-23-058113 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-11-02 | 2023-10-31 | AMLX | FRATES JAMES M | CFO | G - Gift | $0.00 | +11.1K | 11.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-31 | G | A | 11,072 | $0.00 | 11,072 | I By Trust | — | — | (F1) On October 31, 2023, the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person served as trustee and sole annuitant, liquidated and returned 8,410 shares to the Reporting Person as an annuity payment, transferring the remaining 11,072 shares to the FRATES FAMILY 2013 IRREV TRUST for no consideration. (F2) Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |